Apatinib Mesylate
DrugApatinib orally 500mg once daily half an hour after meal
NCT Number: NCT04260113
Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced chondrosarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This study summarizes the experience of two Peking University affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated chondrosarcoma.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Musculoskeletal Tumor Center of Peking University People's Hospital, Beijing, Beijing Municipality, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Apatinib orally 500mg once daily half an hour after meal
Time frame: 6 months
from initial treatment to date of recorded progression or death or last follow-up
Time frame: 5 years
from initial treatment to death or last follow-up
Time frame: 6 months
CR+PR according to RECIST 1.1
Time frame: 6 months
CR+PR+SD according to RECIST 1.1
Peking University People's Hospital
Other
The Effectivity and Toxicity of Apatinib for Unresectable Advanced Chondrosarcoma: a Multicentric Retrospective Study
Acronym: AIAC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06120712
Adverse Drug Event, Chemically-Induced Disorders
Beijing, China
View Trial DetailsNCT05417750
Advanced Solid Tumor, Adverse Drug Event
Beijing, Beijing Municipality, China
View Trial DetailsNCT03491371
Chondrosarcoma, Efficacy
Beijing, China
View Trial DetailsNCT07557966
Efficacy, Fluconazole
Tanta, El-Gharbia, Egypt
View Trial Details